BCG042 / Biocytogen - LARVOL DELTA

BCG042: A promising anti-LILRB4 antibody with ADCC enhancement demonstrates superior efficacy in preclinical models of monocytic AML (AACR 2026) - "Monocytic acute myeloid leukemia (AML; FAB M4/M5) is an aggressive disease characterized by limited response to standard therapies, including chemotherapy and hypomethylating agent (HMA) plus venetoclax combinations. This dual mechanism of action translates into superior antitumor efficacy and a favorable therapeutic window in preclinical models. These compelling data provide a strong rationale for the clinical development of BCG042 as a novel therapeutic for patients with relapsed/refractory monocytic AML."

ADC • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • APOE • LILRB4